A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults

NCT05693272 on ClinicalTrials.gov Phase 1 University of Saskatchewan (academic or other) Started 2023-01-31 Completed

Among the lowest-risk 1% of active trials

Model scores of the 29,894 trials active now.

Model score 2% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (340 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

How it ended

Completed on 2024-06-04, after 2023-01-31 start.

The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.

Termination over time, as the model saw it at the start

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-06-04. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: adjuvantbreasttherapyeligiblechemotherapy
Phrases that lowered it: vaccinevaccinationimmunogenicityhealthyparticipants
Accepts healthy volunteers: Yes (lowers risk) · Who can join
Primary purpose: prevention (lowers risk) · Design
Phase: 1 (lowers risk) · Design
Sponsor's past termination rate: 5.1% (lowers risk) · Sponsor's track record
Drug's FAERS reports marked serious: 54.9% (lowers risk) · Drug's FDA history
Has a data monitoring committee: Yes (raises risk) · Design
Sponsor type: academic or other (raises risk) · Sponsor's track record
Trials the sponsor started in the prior 2 years: 25 (lowers risk) · Sponsor's track record
Drug's FAERS reports with a death: 4.0% (lowers risk) · Drug's FDA history
Disease area, cancer: No (lowers risk) · Disease area
Number of arms: 4 (lowers risk) · Design
Minimum age: 18 (raises risk) · Who can join
Sponsor's past trials: 136 (lowers risk) · Sponsor's track record
Blinding: quadruple (lowers risk) · Design
Maximum age: 65 (raises risk) · Who can join
Design: sequential (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase: 1 (typical: 2)
Number of arms: 4 (typical: 2)
Allocation: randomized
Design: sequential (typical: parallel)
Primary purpose: prevention (typical: treatment)
Blinding: quadruple (typical: none)
Has a data monitoring committee: Yes (typical: 56% yes)
Responsible party: principal investigator (typical: sponsor)
Collaborators: 2 (typical: 0)
Keywords listed: 1

Who can join

Minimum age: 18
Maximum age: 65 (typical: 71)
Sex: all
Accepts healthy volunteers: Yes (typical: 9% yes)

Sponsor's track record

Sponsor type: academic or other
Sponsor's past trials: 136 (typical: 32)
Sponsor's past termination rate: 5.1% (typical: 9.9%)
Trials the sponsor started in the prior 2 years: 25 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history: 1
Drug has FAERS history: Yes (typical: 64% yes)
Drug's FAERS reports before start: 5115 (typical: 2148)
Drug's FAERS reports in the prior 12 months: 3481 (typical: 412.5)
Drug's FAERS reports marked serious: 54.9% (typical: 85.6%)
Drug's FAERS reports with a death: 4.0% (typical: 15.9%)

Disease area and drugs

Disease areas: infectious disease, respiratory
Drugs matched to FDA substances: covid19 vaccine

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

Clinical Trial to Study the COVAC-2 Booster Dose (for COVID-19) in Generally Healthy Adults. NCT05226702 · started 2022 · scored riskier than 0% of active trials completed
A Clinical Trial of COVAC-2 in Healthy Adults NCT04702178 · started 2021 · scored riskier than 2% of active trials completed
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells) NCT04904471 · started 2021 · scored riskier than 1% of active trials completed
A Clinical Trial of COVAC-2 in Adults NCT05209009 · started 2022 · scored riskier than 2% of active trials completed
Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines NCT05372588 · started 2022 · scored riskier than 0% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.